《新股消息》宜明昂科-B(01541.HK)今起招股 一手入場費3,758元
生物技術公司宜明昂科-B(01541.HK)公布招股詳情,擬全球發售1,714.72萬股,香港公開發售佔一成,國際發售佔九成。招股價每股18.6元。該股每手200股計,一手入場費3,757.52元。今日(24日)起招股,下周二(29日)中午截止,預期9月5日掛牌。聯席保薦人為摩根士丹利及中金。
是次公司上市引入4名基石投資者,包括Harvest、藥明生物(02269.HK)旗下Wuxi Venture、榮昌生物(09995.HK)子公司、昆翎,共認購公司2,970萬美元股份。
公司料上市淨集資約2.3億元,當中約40%將用於核心產品IMM01 (SIRPα-Fc融合蛋白)正在進行及計劃開展的臨床試驗、籌備註冊申請以及計劃的商業化上市;約28%將用於核心產品IMM0306 (CD47×CD20)、IMM2902 (CD47×HER2)及IMM2520 (CD47×PD-L1)正在進行及計劃開展的臨床試驗、籌備註冊申請以及計劃的商業化上市;約10%將用於IMM47 (CD24單克隆抗體)計劃開展的臨床試驗;
此外,約5%將用於IMM2510 (VEGF×PD-L1)及IMM27M (CTLA4 ADCC增強型單克隆抗體)正在進行的臨床試驗;約7%將用於建設上海張江科學城的新生產設施;約5%將用於多個臨床前及發現階段資產(包括但不限於IMM4701、IMM51、IMM38、IMM2547、IMM50 及IMM62)的持續臨床前研發以及CMC以支持臨床試驗,包括各種資產的關鍵試驗;約5%將用於營運資金及一般公司用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.